Compare Stocks → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:COGTNASDAQ:ETNBNASDAQ:FIXXNASDAQ:KVSANASDAQ:VERA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$6.54-6.0%$7.04$3.67▼$13.50$625.29M1.52.04 million shs1.78 million shsETNB89bio$8.58-3.8%$11.09$6.57▼$22.93$816.99M1.041.23 million shs871,176 shsFIXXHomology Medicines$0.52$0.46▼$1.48$54.33M-0.1390,307 shs401,400 shsKVSAKhosla Ventures Acquisition$10.74$10.68$9.94▼$11.22$20.62M0.07137,560 shs6,300 shsVERAVera Therapeutics$39.95+1.1%$43.47$6.07▼$50.78$2.18B1.051.29 million shs773,060 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-2.25%+7.74%+8.92%+57.11%-35.50%ETNB89bio-4.19%-4.80%-22.43%-12.89%-43.18%FIXXHomology Medicines0.00%0.00%+0.77%+215.24%+88.83%KVSAKhosla Ventures Acquisition0.00%0.00%0.00%0.00%+5.50%VERAVera Therapeutics+1.00%-7.16%-3.61%+132.20%+517.50%Pentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGTCogent Biosciences1.5408 of 5 stars4.41.00.00.01.30.00.6ETNB89bio1.9208 of 5 stars4.41.00.00.01.91.70.0FIXXHomology Medicines1.5458 of 5 stars3.30.00.04.80.00.80.6KVSAKhosla Ventures AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AVERAVera Therapeutics0.5601 of 5 stars1.51.00.00.02.25.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences2.71Moderate Buy$13.67108.97% UpsideETNB89bio2.71Moderate Buy$29.00238.00% UpsideFIXXHomology Medicines2.50Moderate Buy$0.75∞ UpsideKVSAKhosla Ventures AcquisitionN/AN/AN/AN/AVERAVera Therapeutics3.00Buy$32.29-19.18% DownsideCurrent Analyst RatingsLatest COGT, KVSA, ETNB, FIXX, and VERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024ETNB89bioBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$30.004/5/2024ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$29.004/5/2024VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$56.003/27/2024ETNB89bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.003/27/2024VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $56.003/21/2024VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$21.00 ➝ $34.003/13/2024ETNB89bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.003/6/2024ETNB89bioEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$29.00 ➝ $37.003/5/2024ETNB89bioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform3/4/2024ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$29.003/1/2024ETNB89bioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$15.00 ➝ $14.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/AETNB89bioN/AN/AN/AN/A$5.75 per shareN/AFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00KVSAKhosla Ventures AcquisitionN/AN/A$0.05 per share203.40($0.22) per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$192.41M-$2.40N/AN/AN/AN/A-86.67%-58.11%5/14/2024 (Estimated)ETNB89bio-$142.19M-$2.01N/AN/AN/AN/A-31.01%-27.84%5/2/2024 (Estimated)FIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%5/9/2024 (Estimated)KVSAKhosla Ventures Acquisition$1.87MN/A0.00∞N/AN/A-68.45%2.96%N/AVERAVera Therapeutics-$95.99M-$2.29N/AN/AN/AN/A-73.33%-50.79%5/9/2024 (Estimated)Latest COGT, KVSA, ETNB, FIXX, and VERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023VERAVera Therapeutics-$0.53-$0.58-$0.05-$0.58N/AN/A2/29/2024Q4 2023ETNB89bio-$0.49-$0.50-$0.01-$0.50N/AN/A2/26/202412/31/2023COGTCogent Biosciences-$0.55-$0.63-$0.08-$0.63N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/AKVSAKhosla Ventures AcquisitionN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A7.097.09ETNB89bio0.0520.0420.04FIXXHomology MedicinesN/A7.257.25KVSAKhosla Ventures AcquisitionN/A0.250.25VERAVera Therapeutics0.497.717.71OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/AETNB89bioN/AFIXXHomology Medicines31.32%KVSAKhosla Ventures Acquisition54.76%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences5.10%ETNB89bio4.40%FIXXHomology Medicines16.10%KVSAKhosla Ventures Acquisition17.00%VERAVera Therapeutics21.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences16495.61 million90.74 millionOptionableETNB89bio7095.22 million91.04 millionOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableKVSAKhosla Ventures AcquisitionN/A1.92 million1.59 millionOptionableVERAVera Therapeutics5154.45 million42.64 millionOptionableCOGT, KVSA, ETNB, FIXX, and VERA HeadlinesSourceHeadlineVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from Analystsamericanbankingnews.com - April 21 at 2:12 AMRusfertide Shows Promise in Polycythemia Verarenalandurologynews.com - April 17 at 10:25 PMVera Therapeutics (NASDAQ:VERA) Trading Down 3% on Insider Sellingamericanbankingnews.com - April 16 at 1:26 AMVera Therapeutics (NASDAQ:VERA) Shares Down 3% After Insider Sellingmarketbeat.com - April 15 at 10:35 AMVera Therapeutics executive sells over $228k in company stockinvesting.com - April 14 at 9:09 AMVera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells $228,560.00 in Stockamericanbankingnews.com - April 14 at 4:42 AMVanguard Group Inc. Raises Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)marketbeat.com - April 14 at 4:16 AMWhat about the company Vertex didn’t buy?statnews.com - April 13 at 7:39 PMInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells 5,714 Shares of Stockinsidertrades.com - April 13 at 7:09 AMCould This Stock Be the Next Biotech Buyout?fool.com - April 13 at 5:29 AMInsider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...finance.yahoo.com - April 12 at 10:56 PMJoseph R. Young Sells 5,714 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stockmarketbeat.com - April 12 at 6:34 PMVertex wagers $4.9bn on Alpine kidney disease therapypharmaphorum.com - April 11 at 8:49 PMBiotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Optionsmsn.com - April 11 at 8:49 PM2 Biotech Stocks Driving the Nasdaq Todayschaeffersresearch.com - April 11 at 1:41 PMVera Therapeutics (NASDAQ:VERA) Stock Price Up 7.2%marketbeat.com - April 10 at 3:24 PMAlpine Immune jumps on report of takeover interestmsn.com - April 10 at 1:24 PMVera Therapeutics (NASDAQ:VERA) Shares Gap Down on Insider Sellingmarketbeat.com - April 8 at 10:24 AMVera Therapeutics, Inc. (NASDAQ:VERA) CFO Sells $3,954,187.08 in Stockinsidertrades.com - April 8 at 4:24 AMPosttransplant Skin Disease: Consider Skin Cancer, Infection Risksmedscape.com - April 7 at 8:24 PMCommit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Optionsnasdaq.com - April 7 at 3:24 PMSean Grant Sells 99,828 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stockmarketbeat.com - April 6 at 12:37 AMGuggenheim Reiterates Buy Rating for Vera Therapeutics (NASDAQ:VERA)marketbeat.com - April 5 at 11:10 AMVera Therapeutics (NASDAQ:VERA) Shares Down 5.9% marketbeat.com - April 3 at 4:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCogent BiosciencesNASDAQ:COGTCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.89bioNASDAQ:ETNB89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Homology MedicinesNASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Khosla Ventures AcquisitionNASDAQ:KVSAKhosla Ventures Acquisition Co. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Khosla Ventures Acquisition Co. was incorporated in 2021 and is based in Menlo Park, California.Vera TherapeuticsNASDAQ:VERAVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.